Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/AKT/mammalian target of rapamycin (mTOR) in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeon, Minjeong, Kim, Youngmi, Jung, Hyun Suk, Jeoung, Dooil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311641/
https://www.ncbi.nlm.nih.gov/pubmed/32626712
http://dx.doi.org/10.3389/fcell.2020.00486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311641/
https://www.ncbi.nlm.nih.gov/pubmed/32626712
http://dx.doi.org/10.3389/fcell.2020.00486

Ejemplares similares